EN DE
STOCK COMPARISON

Aarti Pharmalabs vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Aarti Pharmalabs (AARTIPHARM) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 13, 2026.

As of Aug 13, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Aarti Pharmalabs trades at ₹889 versus a fair value of ₹320 (-64%), while Jiangsu Hengrui Medicine Co trades at ¥54.36 versus ¥25.94 (-52%).
Aarti Pharmalabs
AARTIPHARM.NSE · INR · Health Care
-64%
upside to fair value
overvalued
Price₹889
Fair Value₹320
Quality45/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-52%
upside to fair value
overvalued
Price¥54.36
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Aarti PharmalabsJiangsu Hengrui Medicine Co
Valuation
36.3×P/E (TTM)43.6×
3.48×P/S (TTM)10.84×
2.98×P/B5.76×
16.2×EV/EBITDA33.0×
PEG0.93×
0.5%Dividend yield0.4%
₹3.50Dividend per share¥0.20
Profitability
10%Net margin25%
18%Operating margin32%
8%Return on equity15%
6%Return on assets9%
Growth
3%Revenue growth (YoY)13%
-2.2%Avg. growth/yr (3Y)13.9%
Avg. growth/yr (5Y)2.5%
Balance & size
0.09×Debt / equity
$666MMarket cap$52B
weakGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 5 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Aarti Pharmalabsof which business quality 47 · market factors 58 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 47
ProfitabilityMargins and returns on capital today
42
63
Quality GrowthAre margins and returns improving?
29
41
CashflowEarnings quality: real cash, not paper profit
31
82
Fin. StrengthBalance sheet, leverage, solvency risk
70
100
InvestmentDisciplined investing over empire-building
22
27
Low VolatilityCalm price path (market factor)
67
78
MomentumPrice trend over the last 3–12 months (market factor)
51
37
52W MomentumDistance to the 52-week high (market factor)
60
30
Net IssuanceBuybacks instead of dilution
81
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Aarti Pharmalabs

Earnings-Based₹217
Dividend Discount₹43.13
Multiples₹416
Asset-Based₹157
Economic Profit₹245
Growth Earnings₹320

14 of 14 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Aarti Pharmalabs
Bear ₹224Fair Value ₹320Bull ₹416
₹889 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.36 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Aarti Pharmalabs · Health Care

Quality score45 · below median
Fair value upside-64% · bottom 25%

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-52% · below median

Bottom line

As of Aug 13, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Aarti Pharmalabs trades at ₹889 versus a fair value of ₹320 (-64%), while Jiangsu Hengrui Medicine Co trades at ¥54.36 versus ¥25.94 (-52%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.